{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-006455","form_type":"8-K","ticker":null,"cik":"0001783032","company_name":"Elevation Oncology, Inc.","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.076763+00:00","generated_at":"2026-06-03T00:46:24.143696+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Elevation Oncology Q1 net loss $10.7M; cash $104.1M; EO-3021 trial ongoing","bullets":["Net loss of $10.7M improved from $17.1M in Q1 2023; R&D expenses $6.0M, G&A $3.9M.","Cash and marketable securities $104.1M at March 31, 2024; raised $44.2M YTD via ATM, extending runway into 2026.","Enrollment ongoing in Phase 1 trial of EO-3021 (Claudin 18.2 ADC); initial safety/efficacy data expected by mid-3Q 2024.","Presented preclinical proof-of-concept for HER3-ADC program at AACR; development candidate nomination planned for 2H 2024.","Plans to share details of EO-3021 combination study in 1H 2024; additional data expected in 1H 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-006455","json":"https://secwatch.observer/filing/0001558370-24-006455.json","markdown":"https://secwatch.observer/filing/0001558370-24-006455.md","text":"https://secwatch.observer/filing/0001558370-24-006455.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783032/000155837024006455/0001558370-24-006455-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783032/000155837024006455/elev-20240502x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T00:46:24.143696+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8b62f89802e9922489ef3b4658bbc3c88608d61b","claim":"Elevation Oncology, Inc. reported financial results for the first quarter ended March 31, 2024.","evidence_excerpt":"On May 2, 2024, Elevation Oncology, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1783032/000155837024006455/0001558370-24-006455-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}